Korea launches Post-Market safety study of Pfizer's COVID vaccine

NCT ID NCT06613984

Ongoing Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study monitors the safety of the Comirnaty (Bretovameran) COVID-19 vaccine in 660 Korean participants aged 12 and older. Researchers will track side effects like injection site reactions and serious adverse events for up to 28 days after each dose. The goal is to identify any safety issues in real-world use after the vaccine was already approved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Comirnaty (Bretovameran) COVID-19 vaccine
What this could lead to: If successful, this study will confirm the vaccine's safety in a real-world Korean population, supporting continued use.
What could go wrong: This is an observational safety study, not designed to test new efficacy. It may not detect rare or long-term side effects due to limited size and duration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 VACCINATION

Contacts and locations

Locations

Pfizer

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.